Integrins, a family of heterodimeric adhesion receptors for various extracellular matrices, have repeatedly been linked to being important initiators and promoters of ovarian cancer growth and progression. Aggressive ovarian tumors exhibit significantly elevated levels of several RGD-based integrin family members, including integrins 5-1 and v3 or v5. These adhesion receptors appear to encourage cell adhesion, survival, motility, and invasion during the development of an ovarian tumor or the spread of its metastatic disease. Notably, the activation of FAK and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways, is crucial for the functions of these integrins.
Transmembrane proteins called integrins serve as important receptors for cell-extracellular matrix (ECM) and cell-cell adhesion.These molecules can be modified, and the v integrin family in particular, has shown to have significant effects on fibrosis in a variety of organs and disease states. According to numerous studies, the latent transforming growth factor (TGF)- is activated by the integrins v3, v5, v6, and v8 in pre-clinical fibrosis models, modulating the fibrotic process.
One of the 18 different types of subunits that are known to exist and one of the eight different types of subunits that are known to exist are typically non-covalently paired to form each integrin. There are currently 24 different heterodimers in total. The fact that the v subunit can form heterodimers with the 1, 3, 5, 6 or 8 subunits and that the 1 subunit can associate with a wide variety of subunits from 1 to 11 shows that not all theoretically possible and subunit pairs form. It's intriguing to note that a variety of v integrins appear to share a common function in TGF- activation.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V56059 | LDV-FITC | 1207610-07-8 | LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide. |
|
V3005 | Leukadherin-1 | 344897-95-6 | Leukadherin-1,formerly known as LA1, isa novel and specific agonist of Complement receptor 3 (CR3)and the leukocyte surface integrin CD11b/CD18 that enhances leukocyte adhesion to ligands and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. |
|
V34110 | Lifitegrast (SAR 1118; SHP-606) | 1025967-78-5 | Lifitegrast (formerly SAR 1118;SAR 1118-023;SAR-1118; trade name Xiidra) is a novel and potent integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist approved in 2016 for the the treatment of Dry Eye Disease. |
|
V51833 | Lys-Gln-Ala-Gly-Asp-Val | 80755-87-9 | Lys-Gln-Ala-Gly-Asp-Val (KQAGDV) is the six most carboxyl-terminal amino acid (AA)s in the fibrinogen γ-chain sequence. |
|
V3953 | MK-0429 | 227963-15-7 | MK-0429 is a compound that was originally developed as a selective and potent αvβ3 inhibitor for the treatment of osteoporosis, on renal function and fibrosis. |
|
V75802 | mP6 (Myr-FEEERA-OH) | 2700321-79-3 | mP6 (Myr-FEEERA-OH) is a myristoylated peptide. |
|
V80983 | Obtustatin | Obtustatin is a 41-residue non-RGD disintegrin. | |
|
V76685 | Obtustatin triacetate | Obtustatin triacetate is a 41-residue non-RGD disintegrin. | |
|
V41069 | Odulimomab (anti-LFA1) | 159445-64-4 | Odulimomab (anti-LFA1) is an anti-LFA-1 monoclonal antibody (mAb). |
|
V56054 | Orbofiban | 163250-90-6 | Orbofiban is an orally bioactive platelet membrane glycoprotein IIb/IIIa antagonist that can inhibit platelet aggregation. |
|
V53309 | Orbofiban acetate | 163250-91-7 | Orbofiban acetate is an orally bioactive platelet membrane glycoprotein IIb/IIIa antagonist that can inhibit platelet aggregation. |
|
V26983 | OSU-T315 (1,5-regioisomer) | 1333146-24-9 | OSU-T315 (1,5-regioisomer) is anovel, potent and specific small molecule inhibitor of Integrin-linked kinase (ILK) with an IC50 of 0.6 μM,suppressing cancer cell proliferation in vitro and in vivo and inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). |
|
V31818 | OSU-T315 (ILK-IN-1) | 2070015-22-2 | OSU-T315 (ILK-IN-1) is a novel, potent and specific small molecule inhibitor of Integrin-linked kinase (ILK) with an IC50 of 0.6 μM,suppressing cancer cell proliferation in vitro and in vivo and inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). |
|
V35031 | PLN-1474 | 2408065-32-5 | PLN-1474 (compound 1) is an orally bioactive, selective av 1 integrin inhibitor (antagonist) with IC50 of <50 nM. |
|
V6140 | Pyrintegrin | 1228445-38-2 | Pyrintegrin, aβ1-integrin agonist, is a potent and cell-permeable promoter of the adhesion of individually dissociated hESCs on matrigel- or laminin-, but not gelatin-coated surfaces, substantially reducing trypsinization-induced apoptosis. |
|
V8005 | QLT0267 | 6975-75-3 | ILK-IN-3 is an orally bioactive integrin-linked kinase (ILK) inhibitor. |
|
V81277 | R-BC154 acetate | R-BC154 acetate is a selective fluorescent α9β1 integrin antagonist. | |
|
V56053 | REDV | 107978-83-6 | REDV is the minimally active sequence within the CS5 site of the alternatively spliced type III linker (IIICS) region of fibronectin. |
|
V76563 | REDV TFA | REDV TFA is the minimally active sequence within the CS5 site of the alternatively spliced type III linker (IIICS) region of fibronectin. | |
|
V1597 | RGD (Arg-Gly-Asp) | 99896-85-2 | RGD (Arg-Gly-Asp) is a tripeptide that is the most common peptide motif responsible for cell adhesion to the ECM-extracellular matrix. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
